卡培他滨与替吉奥对晚期胃癌的临床疗效比较  

The clinical observation of capecitabine and S-1 in the treatment of advanced gastric cancer

作　　者：杨洁[1] 曹凤军[2] 

机构地区：[1]湖北医药学院附属人民医院健康管理中心,湖北十堰442000 [2]湖北医药学院附属人民医院肿瘤中心,湖北十堰442000

出　　处：《临床消化病杂志》2016年第5期290-292,共3页Chinese Journal of Clinical Gastroenterology

摘　　要：[目的]观察比较卡培他滨与比替吉奥对晚期胃癌的临床疗效及其毒副反应情况。[方法]选取52例晚期胃癌患者,随机分为卡培他滨组和替吉奥组,比较2组患者治疗后效果及毒副反应发生情况。[结果]卡培他滨组治疗有效率为38.5%、疾病控制率为65.4%,替吉奥组治疗有效率34.6%、疾病控制率为57.7%,2组患者治疗有效率、疾病控制率比较差异均无统计学意义(P>0.05);卡培他滨组骨髓抑制、胃肠道反应、手足综合征、口腔炎等毒副反应发生率与替吉奥组比较差异均无统计学意义(P>0.05)。[结论]卡倍他滨或替吉奥治疗晚期胃癌疗效相当,毒副反应无明显差异,均可用于晚期胃癌的化疗用药。[Objective]To evaluate the efficacy and safety of capecitabine or S-1 combined with oxaliplatin or cisplatin in the treatment of advanced gastric cancer. [Methods]Fifty-two patients with advanced gastric cancer in Medical Oncology of the hospital during July. 2012 and Jun. 2015 were involved and randomly divided them to XELOX group and S1 group. After treatment, the therapeutic effects and occurrence of complications of patients in the two groups were compared. [Results]The efficiency rate and tumor growth control rate in the Capecitabine group were 38.5 %, 65.4%. The efficiency rate and tumor growth control rate in S1 group were 36.4%, 57.7%. The difference was not statistically significant between the two groups（P〈0. 05）. No significant difference was found in toxicity between the two groups. [Conclusion]Patients with advanced gastric cancer can benefit from oral oteracil or capecitabine monotherapy with minimal adverse events. The treatment is well tolerated.

关 键 词：胃癌 卡倍他滨 替吉奥 

分 类 号：R735.2[医药卫生—肿瘤]